Cancer Research Meeting Calendar  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ladner, R. D.
Right arrow Articles by Lenz, H.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ladner, R. D.
Right arrow Articles by Lenz, H.-J.
[Cancer Research 60, 3493-3503, July 1, 2000]
© 2000 American Association for Cancer Research


Experimental Therapeutics

dUTP Nucleotidohydrolase Isoform Expression in Normal and Neoplastic Tissues: Association with Survival and Response to 5-Fluorouracil in Colorectal Cancer

Robert D. Ladner1, Frank J. Lynch, Susan Groshen, Yi Ping Xiong, Andrew Sherrod, Salvatore J. Caradonna, Jan Stoehlmacher and Heinz-Josef Lenz

Department of Molecular Biology, at the University of Medicine and Dentistry of New Jersey, School of Osteopathic Medicine, Stratford, New Jersey 08084 [R. D. L., S. J. C.]; QualTek Molecular Laboratories, Inc., Santa Barbara, California 93111 [F. J. L.]; and Division of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, University of Southern California School of Medicine, Los Angeles, California 90033 [S. G., Y. P. X., A. S., J. S., H-J. L.]

Aberrant dUTP metabolism plays a significant role in the underlying molecular mechanisms of cell killing mediated by inhibitors of thymidylate biosynthesis. dUTP nucleotidohydrolase (dUTPase) is the key regulator of dUTP pools, and significant evidence exists suggesting that the expression of this enzyme may be an important determinant of cytotoxicity mediated by inhibitors of thymidylate synthase (TS). In this study, we have determined the expression patterns of dUTPase in normal and neoplastic tissues and examined the association between dUTPase expression and response to 5-fluorouracil (5-FU)-based chemotherapy and overall survival in colorectal cancer.

Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections using a monoclonal antibody (MAb), DUT415, that cross-reacts with both nuclear and mitochondrial isoforms of human dUTPase. Nuclear and cytoplasmic staining was observed in both normal and neoplastic tissues. In normal tissues, nuclear dUTPase staining was observed exclusively in replicating cell types. This observation is in agreement with cell culture studies where expression of the nuclear isoform (DUT-N) is proliferation dependent. In contrast, cytoplasmic expression of dUTPase does not correlate with proliferation status and was observed in tissues rich in mitochondria. Consistent with this observation, cell culture studies reveal that the mitochondrial isoform (DUT-M) is expressed constitutively, independent of cell cycle status. These data suggest that in normal tissues, nuclear staining with the DUT415 antibody represents the DUT-N isoform, whereas cytoplasmic staining represents the DUT-M isoform.

In colon cancer tumor specimens, expression of dUTPase was shown to be highly variable in both amount and intracellular localization. Patterns of dUTPase protein expression observed included exclusive nuclear, exclusive cytoplasmic, and combined nuclear and cytoplasmic staining. Thus, immunohistochemical detection of dUTPase in colon cancers provides distinct intracellular phenotypes of expression that may be of significant prognostic value.

To examine the association between dUTPase expression and response to 5-FU-based chemotherapy and overall survival, we initiated a retrospective study including tumor specimens from 20 patients who had received protracted infusion of 5-FU and leucovorin for treatment of metastatic colon cancer. Positive nuclear staining was found in 8 patients, whereas 12 lacked nuclear expression. Of the patients lacking nuclear dUTPase expression, 6 responded to 5-FU-based chemotherapy, 4 had stable disease, and 2 had progressive disease. Of the patients presenting positive nuclear dUTPase expression, 0 responded to chemotherapy, 1 had stable disease, and 7 had progressive disease (P = 0.005). The median survival for patients with tumors lacking nuclear staining was 8.5 months and 6.9 months for patients with tumors demonstrating positive nuclear dUTPase expression (P = 0.09). Time to progression was significantly longer for patients with tumors lacking nuclear staining (P = 0.017). Variable cytoplasmic dUTPase expression was observed in these tumors; however, there was no apparent association with clinical response or survival in this limited study. Nuclear dUTPase staining within these tumors was also associated with TS gene expression (P = 0.06).

This study demonstrates that low intratumoral levels of nuclear dUTPase protein expression is associated with response to 5-FU-based chemotherapy, greater time to progression, and greater overall survival in colorectal cancer. Conversely, high levels of nuclear dUTPase protein expression predict for tumor resistance to chemotherapy, shorter time to progression, and shorter overall survival. This report represents the first clinical study implicating dUTPase overexpression as a mechanism of resistance to TS inhibitor-based chemotherapy.




This article has been cited by other articles:


Home page
J. Clin. Pathol.Home page
A Kawahara, Y Akagi, S Hattori, T Mizobe, K Shirouzu, M Ono, T Yanagawa, M Kuwano, and M Kage
Higher expression of deoxyuridine triphosphatase (dUTPase) may predict the metastasis potential of colorectal cancer
J. Clin. Pathol., April 1, 2009; 62(4): 364 - 369.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
P. M. Wilson, W. Fazzone, M. J. LaBonte, H.-J. Lenz, and R. D. Ladner
Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage
Nucleic Acids Res., January 1, 2009; 37(1): 78 - 95.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
P. M. Wilson, W. Fazzone, M. J. LaBonte, J. Deng, N. Neamati, and R. D. Ladner
Novel opportunities for thymidylate metabolism as a therapeutic target
Mol. Cancer Ther., September 1, 2008; 7(9): 3029 - 3037.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Toth, B. Varga, M. Kovacs, A. Malnasi-Csizmadia, and B. G. Vertessy
Kinetic Mechanism of Human dUTPase, an Essential Nucleotide Pyrophosphatase Enzyme
J. Biol. Chem., November 16, 2007; 282(46): 33572 - 33582.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
N. Senzer, J. Nemunaitis, M. Nemunaitis, J. Lamont, M. Gore, H. Gabra, R. Eeles, N. Sodha, F. J. Lynch, L. A. Zumstein, et al.
p53 therapy in a patient with Li-Fraumeni syndrome
Mol. Cancer Ther., May 1, 2007; 6(5): 1478 - 1482.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. A. Fischer, S. Muller-Weeks, and S. J. Caradonna
Fluorodeoxyuridine Modulates Cellular Expression of the DNA Base Excision Repair Enzyme Uracil-DNA Glycosylase.
Cancer Res., September 1, 2006; 66(17): 8829 - 8837.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
L. Seiple, P. Jaruga, M. Dizdaroglu, and J. T. Stivers
Linking uracil base excision repair and 5-fluorouracil toxicity in yeast
Nucleic Acids Res., January 10, 2006; 34(1): 140 - 151.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
M. Guillet, P. A. Van Der Kemp, and S. Boiteux
dUTPase activity is critical to maintain genetic stability in Saccharomyces cerevisiae.
Nucleic Acids Res., January 1, 2006; 34(7): 2056 - 2066.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. A. Parsels, J. D. Parsels, D. C.-H. Tai, D. J. Coughlin, and J. Maybaum
5-Fluoro-2'-Deoxyuridine-Induced cdc25A Accumulation Correlates with Premature Mitotic Entry and Clonogenic Death in Human Colon Cancer Cells
Cancer Res., September 15, 2004; 64(18): 6588 - 6594.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. E. Koehler and R. D. Ladner
Small Interfering RNA-Mediated Suppression of dUTPase Sensitizes Cancer Cell Lines to Thymidylate Synthase Inhibition
Mol. Pharmacol., September 1, 2004; 66(3): 620 - 626.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Kovari, O. Barabas, E. Takacs, A. Bekesi, Z. Dubrovay, V. Pongracz, I. Zagyva, T. Imre, P. Szabo, and B. G. Vertessy
Altered Active Site Flexibility and a Structural Metal-binding Site in Eukaryotic dUTPase: KINETIC CHARACTERIZATION, FOLDING, AND CRYSTALLOGRAPHIC STUDIES OF THE HOMOTRIMERIC DROSOPHILA ENZYME
J. Biol. Chem., April 23, 2004; 279(17): 17932 - 17944.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Guo, E. Kotova, Z.-S. Chen, K. Lee, E. Hopper-Borge, M. G. Belinsky, and G. D. Kruh
MRP8, ATP-binding Cassette C11 (ABCC11), Is a Cyclic Nucleotide Efflux Pump and a Resistance Factor for Fluoropyrimidines 2',3'-Dideoxycytidine and 9'-(2'-Phosphonylmethoxyethyl)adenine
J. Biol. Chem., August 8, 2003; 278(32): 29509 - 29514.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. A. Tinkelenberg, M. J. Hansbury, and R. D. Ladner
dUTPase and Uracil-DNA Glycosylase Are Central Modulators of Antifolate Toxicity in Saccharomyces cerevisiae
Cancer Res., September 1, 2002; 62(17): 4909 - 4915.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
Y. Shirota, J. Stoehlmacher, J. Brabender, Y.-P. Xiong, H. Uetake, K. D. Danenberg, S. Groshen, D. D. Tsao-Wei, P. V. Danenberg, and H.-J. Lenz
ERCC1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy
J. Clin. Oncol., December 1, 2001; 19(23): 4298 - 4304.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.